HER2 Biomarkers
AstraZeneca Q2 Revenues Increase 31 Percent
The company reported revenues of $8.22 billion, largely driven by sales of its COVID-19 vaccine, but also due to strong performance of its oncology segment.
Daiichi Sankyo, AstraZeneca Dose First Gastric Cancer Patient in Phase III Enhertu Trial
The randomized trial is assessing the antibody drug conjugate versus a chemo regimen for advanced, pretreated, HER2-positive gastric or gastroesophageal cancer.
Enhertu Benefits HER2-Positive Colorectal Cancer Patients, ASCO Data Show
The data from the Phase II trial will help drugmakers further refine the drug's dose and eligible population in colorectal cancer.
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Genentech Basket Trial Identifies Impact of Co-Mutations in Dual HER2-Targeted Treatment Response
Researchers studying Perjeta and Herceptin in HER2-positive advanced solid tumors reported that the combination is efficacious in KRAS wild-type tumors.